GEOFF MCDONOUGH - 10 Jan 2025 Form 4 Insider Report for Generation Bio Co. (GBIO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Shawna-Gay White, Attorney-in-Fact
Issuer symbol
GBIO
Transactions as of
10 Jan 2025
Transactions value $
$0
Form type
4
Filing time
14 Jan 2025, 16:05:08 UTC
Previous filing
17 Oct 2024
Next filing
17 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GBIO Common Stock 1,342,492 10 Jan 2025 Direct F1
holding GBIO Common Stock 226,462 10 Jan 2025 By 2018 Trust F2
holding GBIO Common Stock 275,000 10 Jan 2025 By 2020 Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBIO Stock Option (right to buy) Award $0 +901,690 $0 901,690 10 Jan 2025 Common Stock 901,690 $0.926 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,863 shares acquired under the company's employee stock purchase plan since October 15, 2024.
F2 The securities are directly held by the McDonough Family 2018 Irrevocable Trust, or the 2018 Trust. The reporting person is the settlor of the 2018 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2018 Trust, and the 2018 Trust is for the benefit of Graeme and Owen McDonough. The reporting person may be deemed to beneficially own the shares of common stock owned by the 2018 Trust.
F3 The securities are directly held by the McDonough Family 2020 Irrevocable Trust, or the 2020 Trust. The reporting person is the settlor of the 2020 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2020 Trust, and the 2020 Trust is for the benefit of Allison, Graeme and Owen McDonough. The reporting person may be deemed to beneficially own the shares of common stock owned by the 2020 Trust.
F4 The option to purchase 901,690 shares was granted on January 10, 2025. The shares underlying the option vest over four years, with 25% of the shares vesting on January 10, 2026 and the remaining shares vesting in equal quarterly installments thereafter.